Search company, investor...

A&G Pharmaceutical

agrx.net

Founded Year

2000

Stage

Loan | Alive

Total Raised

$3M

Last Raised

$250K | 3 yrs ago

About A&G Pharmaceutical

A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. A&G's therapeutics division is pursuing development of anti-GP88 and other monoclonal antibody drugs for cancer. On the diagnostics side, A&G is currently developing test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88. One of these'"a biopsy test kit currently in clinical trials'"will also serve as a companion diagnostic to anti-GP88 immunotherapy. A&G's Precision Antibody'„ service unit generates revenue to fund the drug development effort by accelerating the creation of novel, customized antibodies for leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G has raised $5.5 million of equity capital and is located in Columbia, Md.

Headquarters Location

9130 Red Branch Road Suite U

Columbia, Maryland, 21045,

United States

410-884-4100

Missing: A&G Pharmaceutical's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: A&G Pharmaceutical's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing A&G Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

A&G Pharmaceutical is included in 3 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

A&G Pharmaceutical Patents

A&G Pharmaceutical has filed 14 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Human cells
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/15/2018

1/17/2023

Monoclonal antibodies, Clusters of differentiation, Immunology, Monoclonal antibodies for tumors, Experimental cancer drugs

Grant

Application Date

10/15/2018

Grant Date

1/17/2023

Title

Related Topics

Monoclonal antibodies, Clusters of differentiation, Immunology, Monoclonal antibodies for tumors, Experimental cancer drugs

Status

Grant

Latest A&G Pharmaceutical News

Identification Of An Internalizing Cancer Target For Novel Antibody Drug Conjugate By A&G Pharmaceutical And Precision Antibody Researchers.

Jun 7, 2021

agpharma.com ) and Precision Antibody ( www.precisionantibody.com ) are pleased to announce the publication, in PLOS One, of their collaborative study regarding the identification of Prostaglandin F2 receptor negative regulator as an internalizing  cancer cell target and the isolation of proprietary internalizing antibody for antibody drug conjugate development. A&G Pharmaceutical is a theranostic target discovery company developing therapeutic and diagnostic products in Oncology. Precision Antibody has developed a customized program to select internalizing antibodies for cell surface targets. This includes a strategized antigen design and immunization program with high throughput targeted screening of internalizing antibodies, clone selection and functional assays. Antibody-Drug Conjugates (ADCs) have recently received increased interest as therapeutic choices in oncology. ADCs are composed of a monoclonal antibody binding to a cell surface target, a linker, and a cytotoxic payload. After binding to its antigen, the mAb induces endocytosis, shuttling the payload inside the cell. Several ADCs have been approved by the Food and Drug Administration as treatment for hematopoietic and solid tumors. The approach centered on the identification of targets internalized and expressed on cancer cells by screening hybridoma libraries developed against cancer cell-surface antigens. Antibody libraries are screened for their ability to bind, internalize, and deliver a cytotoxic payload to specific cancer cells. This approach was used by A&G Pharmaceutical and Precision Antibody to characterize an internalizing monoclonal antibody, identify its target by mass spectrometry as PTGFRN and shows its efficacy as ADC  in vitro and in vivo, for several cancer types including head and neck cancers and spindle cell carcinoma. PTGFRN is a member of cell surface tetraspanins family contributing to many key biological functions linked to adhesion, migration and survival and show promise as therapeutic targets. "We are delighted to have identified PTFGRN as a promising internalizing cancer target that could increase the repertoire of therapeutic options for cancers with unmet needs. After developing diagnostic and therapeutic products for progranulin/GP88, it is exciting to contribute new cancer therapeutic options based on cell-surface protein" declared Dr. Ginette Serrero, A&G Pharmaceutical CEO. For Dr. Jun Hayashi, Precision Antibody President "knowing that Precision internalizing antibody development program led to the discovery of new targeted cancer therapy is rewarding". This study is found in https://journals.plos.org/plosone/article/authors?id=10.1371/journal.pone.0246197 Contact information: kdoubleday@precisionantibody.com . 410-884-4100

A&G Pharmaceutical Frequently Asked Questions (FAQ)

  • When was A&G Pharmaceutical founded?

    A&G Pharmaceutical was founded in 2000.

  • Where is A&G Pharmaceutical's headquarters?

    A&G Pharmaceutical's headquarters is located at 9130 Red Branch Road, Columbia.

  • What is A&G Pharmaceutical's latest funding round?

    A&G Pharmaceutical's latest funding round is Loan.

  • How much did A&G Pharmaceutical raise?

    A&G Pharmaceutical raised a total of $3M.

  • Who are the investors of A&G Pharmaceutical?

    Investors of A&G Pharmaceutical include Paycheck Protection Program, Maryland Department of Business & Economic Development, New England Partners, Crocker Capital and ASM Resources.

  • Who are A&G Pharmaceutical's competitors?

    Competitors of A&G Pharmaceutical include Concert Pharmaceuticals, Stemina Biomarker Discovery, Adastra Pharmaceuticals, OncoMed Pharmaceuticals, Ikaria and 12 more.

Compare A&G Pharmaceutical to Competitors

M
Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

O
Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

N
NanoMedex Pharmaceuticals

NanoMedex uses patented formulation strategies to dissolve drugs in water that are only soluble in fats or lipids. Once dissolved in water, these drugs can be administrated intravenously. In hospitals, intravenous administration is preferred by older patients to eliminate swallowing, by physicians to increase certainty that the correct drug dose is given, and by health care providers to ensure that Medicare reimburses 100 percent of costs (versus 50 percent for oral administration).

T
ThyroChek

ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

E
Eagle Vision Pharmaceutical

Eagle Vision Pharmaceutical Corporation - The Eagle Vision SeeMoreTM imaging agent is a of its kind to harness the power of MRI to provide results in three critical areas: cardiac perfusion, cardiac function and cardiac vessel status, which today require multiple tests that cost thousands of dollars. The metabolic imaging agent based on manganese uptake is being tested in phase II clinical studies. In addition, the company has preclinical data for its use in solid tumor imaging in breast cancer, as well as hepatic disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.